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Abstract
Higher levels of circulating adiponectin have been related to lower risk of colorectal cancer in 
several prospective cohort studies, but it remains unclear whether this association may be causal. 
We aimed to improve causal inference in a Mendelian Randomization meta-analysis using nested 
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case-control studies of the European Prospective Investigation into Cancer and Nutrition (EPIC, 
623 cases, 623 matched controls), the Health Professionals Follow-up Study (HPFS, 231 cases, 
230 controls) and the Nurses’ Health Study (NHS, 399 cases, 774 controls) with available data on 
pre-diagnostic adiponectin concentrations and selected single nucleotide polymorphisms (SNPs) in 
the ADIPOQ gene. We created an ADIPOQ allele score that explained approximately 3% of the 
interindividual variation in adiponectin concentrations. The ADIPOQ allele score was not 
associated with risk of colorectal cancer in logistic regression analyses (pooled OR per score-unit 
unit 0.97, 95% CI 0.91, 1.04). Genetically determined two-fold higher adiponectin was not 
significantly associated with risk of colorectal cancer using the ADIPOQ allele score as 
instrumental variable (pooled OR 0.73, 95% CI 0.40, 1.34). In a summary instrumental variable 
analysis (based on previously published data) with higher statistical power, no association between 
genetically determined two-fold higher adiponectin and risk of colorectal cancer was observed 
(0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 1.01 in men). Thus, our study does not 
support a causal effect of circulating adiponectin on colorectal cancer risk. Due to the limited 
genetic determination of adiponectin, larger Mendelian Randomization studies are necessary to 
clarify whether adiponectin is causally related to lower risk of colorectal cancer.
Keywords
adiponectin; ADIPOQ; colorectal cancer; Mendelian Randomization
Background
Obesity, in particular abdominal obesity is an established risk factor for the development of 
colorectal cancer (1). Although the underlying biological mechanisms have not been fully 
elucidated, it is widely accepted that the adipose tissue, particularly visceral adipose tissue, 
is an active endocrine organ secreting various bioactive substances collectively named 
adipokines, which may provide an important link between body fatness and colorectal 
cancer risk (2). In contrast to many other adipokines, adiponectin expression is suppressed in 
obesity and plasma concentrations are lower in obese than in lean individuals (3). 
Adiponectin has been suggested to play a protective role in the development of cancer either 
directly through inhibition of cell growth (e.g. via RAS signaling (4)) and induction of 
apoptosis, or indirectly through improved insulin sensitivity and reduced inflammation (5). 
The association between circulating adiponectin concentrations and risk of colorectal cancer 
has been investigated in several prospective cohort studies, with mixed findings: Higher 
plasma adiponectin concentrations were associated with lower risk of colorectal cancer 
(slightly stronger in women than men, but no statistically significant sex-differences) in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) (6) and in the Health 
Professionals Follow-up study (HPFS), while no association was observed in the Nurses’ 
Health Study (NHS) (7). A meta-analysis of ten case-control or nested case-control studies 
(not including the data from EPIC, NHS or HPFS) reported a statistically significant two 
percent lower risk of colorectal cancer or adenoma for a 1 μg/mL increment in adiponectin 
in men whereas among women no association was observed (8).
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To date, it remains unclear whether adiponectin plays a causal role in the development of 
colorectal cancer not least because it cannot be excluded that residual confounding and/or 
reverse causation bias might have introduced bias in observational associations (Figure 1). 
Mendelian Randomization is a statistical approach that can improve causal inference (9). 
The principle is that under the assumption of the random assortment of alleles at conception, 
genetic variants that are associated with biomarker levels can be used as relatively unbiased 
proxies for biomarker concentrations due to two advantages. First, since the genotype of an 
individual is determined at gamete formation and cannot be altered later on (e.g. by disease 
onset), there is no possibility of reverse causation (10). Second, the relationship between 
genetic variants and disease risk can be assumed to be not confounded by lifestyle and 
behavioral factors that can confound the observed association between circulating 
biomarkers and risk of disease. Therefore, using genetic variants associated with circulating 
biomarker concentrations in a Mendelian Randomization approach may provide insight into 
the underlying causal relationships by circumventing reverse causation and residual 
confounding. In a pooled analysis from the Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO), which includes data from NHS, HPFS and eight other studies 
comprising overall more than 7,000 colorectal cancer cases and approximately the same 
number of controls, genetic variants in the gene encoding adiponectin (ADIPOQ) were not 
associated with colorectal cancer risk (11). However, a simultaneous analysis of adiponectin 
concentrations, ADIPOQ genetic variants and colorectal cancer was not conducted, because 
adiponectin plasma levels were only available in a subset of included studies, namely NHS 
and HPFS. With a dataset including individual participant data on genetic variants, 
biomarker concentration and disease outcome, a traditional Mendelian Randomization 
analysis taking into account the actual strength of the association between ADIPOQ-SNPs 
and adiponectin concentrations in the study population can be performed, which has the 
advantage that instrumental variable assumptions can be directly assessed (12, 13). The aim 
of our investigation was therefore to improve causal inference in the association between 
circulating adiponectin and colorectal cancer risk using ADIPOQ genetic variants in a 
Mendelian Randomization meta-analysis with individual participant data from the EPIC, 
HPFS and NHS cohorts.
Methods
Study population
The three studies included in the present investigation were all nested case-control studies of 
large prospective cohorts with long follow-up. In all nested case-control studies, colorectal 
cancer was defined according to the International Statistical Classification of Diseases, 
Injury and Causes of Death (ICD-10) as cancers of the colon (C18.0–C18.7), cancers of the 
rectum (C19–C20) and tumors that were overlapping or unspecified (C18.8–C18.9). Blood 
samples were collected prior to diagnosis and matched control participants were selected 
using incidence density sampling, i.e. selection was performed among study participants 
who were alive and free of cancer (except non-melanoma skin cancer) at the time of 
diagnosis of the colorectal cancer case.
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The EPIC study is a large multicenter prospective cohort including more than 520,000 study 
participants from 10 European countries who were aged between 35 and 70 years at 
recruitment which took place from 1992 to 2000(14). Baseline examinations included 
anthropometric measurements, standardized ascertainment of lifestyle characteristics and 
medical history information as well as collection of blood samples. The EPIC study was 
approved by the ethical review board of the International Agency for Research on Cancer 
(IARC, Lyon, France) and the institutional review boards of each participating study center 
and informed consent was obtained from all participants. Incident cancer cases including 
colorectal cancer cases were determined through record linkage with local cancer registries 
in most countries (Denmark, Italy (except Naples), the Netherlands, Norway, Spain, 
Sweden, United Kingdom, complete up to 2003). In some countries (France, Germany, Italy 
(Naples), Greece, complete up to 2002) active follow-up was organized by contact of 
participants or next of kin through mailed questionnaires, followed by verification of self-
reported cases by study physicians using health insurance data, data from cancer and clinical 
registries as well as medical records provided by the treating physicians. In the present 
analysis, colorectal cancer cases with available prediagnostic blood samples and DNA were 
included. As has been described previously (6), the nested case-control design matched each 
case to one control using incidence density sampling. Control participants were selected 
matched on age at blood collection (2 months to 4-year intervals), study center, fasting status 
(<3, 3–6, or>6 hours) as well as menopausal status and hormone use in women. The nested 
case-control study was designed to be applicable for several biomarker studies, which 
explains inclusion of the latter matching criteria which were not relevant for the present 
analysis. The number of cases and matched controls included in the present study is 1,246 
(623 cases, 623 matched controls) which is 52% of the study size of the previous analysis on 
circulating adiponectin and risk of colorectal cancer in EPIC (1,206 cases, 1,206 matched 
controls) (6). This difference is largely explained by unavailability of DNA samples from the 
Danish EPIC centers due to local technical and organizational issues.
The HPFS and NHS are two large US cohort studies, detailed descriptions of which are 
provided elsewhere (15, 16). In brief, the HPFS started in 1986, including 51,529 men aged 
40–75 years, and the NHS started in 1976 and included 121,701 women aged 30–55 years. 
In both cohorts, study participants provided information on medical history and lifestyle at 
recruitment. Since then, follow-up questionnaires were administered biennially to collect 
and update medical and lifestyle information and to elicit medical diagnoses. The follow-up 
rates in both cohorts exceeded 90% in each 2-year cycle and the cumulative follow-up rate 
(percentage of potentially collected person-years) was 94% in HPFS and 93% in NHS. 
Blood specimens were provided by 18,225 HPFS participants (35%) between 1993 and 1995 
and by 32,826 NHS participants (27%) between 1989 and 1990 by overnight courier. Details 
on the procedures of blood collection as well as handling and storage of blood samples have 
been described previously(17, 18). Among the participants for whom blood samples and 
DNA were available, 231 colorectal cancer cases were confirmed after blood collection in 
HPFS (up to January 1st 2008) and 399 in NHS (up to October 1st 2008). For each case up to 
two controls were randomly selected using incidence density sampling. The majority of 
individuals included in the nested case-control studies were of Caucasian ancestry in both 
HPFS (95.5%) and NHS (99.9%). All study participants provided informed consent and the 
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study protocol was approved by the Institutional Review Board of the Brigham and 
Women’s Hospital and the Harvard T.H. Chan School of Public Health. The total number of 
participants in the present investigation is 2,880 (1,253 cases and 1,627 controls), including 
1,246 in EPIC (623 cases and 623 controls), 461 in HPFS (231 cases, 230 controls) and 
1,173 in NHS (399 cases, 774 controls).
Adiponectin measurement
Total circulating adiponectin concentration was measured using enzyme-linked 
immunosorbent assays from ALPCO Diagnostics (Salem, New Hampshire) in the three 
studies (6, 7). Based on quality control samples, interbatch coefficients of variation were 
8.3% in EPIC and 8.6% in HPFS and NHS. Adiponectin measurements in n=300 paired 
samples from HPFS showed high reliability, with intraclass correlation coefficient of 0.85 
when measured within the same persons one year apart (19).
SNP selection and genotyping
In EPIC, a set of tagging SNPs covering variations in the ADIPOQ gene in populations of 
European ancestry was selected using HapMap 22/phase II CEPH population data (Utah 
residents with northern and western European descent) applying stringent criteria (minor 
allele frequency >5% and pairwise r2≥0.8). A total number of 15 SNPs were genotyped 
using TaqMan methodology (genotype call rates >99.2% for all the assays), of which one 
(rs7649121) was not in Hardy-Weinberg equilibrium in control participants (p<0.0001) and 
therefore was excluded from analysis. In HPFS and NHS SNPs in the ADIPOQ gene were 
selected based on previous evidence from genome-wide association studies (GWAS) on 
circulating adiponectin concentrations (20–23). Additional SNPs in adiponectin-related 
genes that have been associated with colorectal cancer risk were genotyped (24–26). A total 
of 19 SNPs were genotyped using Illumina HumanOmniExpress as part of the GECCO 
project (11). Missing SNPs were imputed to HapMap II release 24. All genotyped SNPs 
were in Hardy-Weinberg equilibrium in control participants. Eight ADIPOQ SNPs were 
available in all three included studies (rs1063539, rs16861194, rs822394, rs17300539, 
rs17366568, rs17366743, rs266729, rs1501299) and minor allele frequencies were 
comparable.
Statistical analysis
We created an ADIPOQ allele score which was used to derive Mendelian Randomization 
estimates in two different approaches: Firstly, we analyzed the ADIPOQ allele score in 
relation to colorectal cancer risk. Secondly, we applied an instrumental variable approach, 
simultaneously incorporating the ADIPOQ allele score and plasma adiponectin 
concentrations, to model the association between genetically determined circulating 
adiponectin and colorectal cancer risk. While the first approach, which is considered as an 
equivalent to the intention-to-treat analysis in a randomized controlled trial (27), can only 
test for the existence of a causal association, the second approach aims at estimating the 
magnitude of a causal association (e.g. risk estimate per 2-fold higher genetically 
determined adiponectin) (28).
Nimptsch et al. Page 6
Eur J Epidemiol. Author manuscript; available in PMC 2018 May 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ADIPOQ allele score
The weighted ADIPOQ allele score was constructed by summing alleles that have been 
associated with higher adiponectin with genome-wide significance in a previous meta-
analysis of GWAS on adiponectin levels, using their GWAS-coefficients as weights (20). 
Only SNPs not highly correlated (r2<0.8) were included in the score. For NHS and HPFS, 
the included SNPs were rs17300539, rs17366568, rs266729, rs1501299 and rs6810075. The 
score in EPIC was built using the same SNPs, except that for rs6810075 the proxy SNP 
rs182052 was used. To examine whether the ADIPOQ allele score is independent of 
potentially confounding factors, we compared baseline characteristics in each study across 
score categories (approximate tertiles).
The associations between the individual ADIPOQ SNPs as well as the weighted ADIPOQ 
allele score and adiponectin concentrations were examined using linear regression models 
with robust variance in control participants (29). Adiponectin concentrations were naturally 
log-transformed (because of skewed distribution) and we calculated the estimated relative 
change in percent in adiponectin per minor allele (with genotypes coded 0, 1 or 2 according 
to the number of variant alleles) or per score unit, respectively. In addition, R2 and F-values 
as measures of instrument strength are presented. In the previous publication by Song et al. 
(11) the association between ADIPOQ SNPs and plasma adiponectin concentrations was 
presented for HPFS and NHS, but the here included colorectal cancer controls were only a 
small subset of the individuals included in that analysis.
Association between ADIPOQ allele score and colorectal cancer
The association between the ADIPOQ allele score (per score-unit) in relation to risk of 
colorectal cancer was calculated in each study. In EPIC, we used conditional logistic 
regression conditioning on the matching variables and calculating odds ratios (ORs) and 
95% confidence intervals that approximate incidence rate ratios and can be interpreted as 
relative risks. In HPFS and NHS, we used unconditional logistic regression adjusted for 
matching variables (age at blood draw and date of blood draw) to estimate relative risks. In 
sensitivity analyses, we restricted the logistic regression models to individuals with 
Caucasian ancestry (n=16 excluded in HPFS and n=1 excluded in NHS). Because 
multivariable adjustment is per definition not required in Mendelian Randomization studies, 
only minimally adjusted (conditional logistic regression conditioned on the matching 
variables or unconditional logistic regression adjusted for matching factors) estimates are 
presented. We pooled the study-specific results using a meta-analytic approach with random 
effects (30), thereby also assessing potential heterogeneity across studies.
Instrumental variable analysis
For the joint analysis of adiponectin concentrations, genetic variants of the ADIPOQ gene 
and colorectal cancer risk, we performed an instrumental variable analysis using two-stage 
regression. In the first stage, adiponectin concentrations were predicted based on the 
ADIPOQ allele score by means of linear regression. In order to avoid potential bias (31), the 
first stage regression was performed only in control participants and genetically determined 
adiponectin was predicted for the total study population including participants without 
measured adiponectin. In the second stage, a logistic regression of colorectal cancer on the 
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predicted adiponectin concentrations was performed in each study. In EPIC, the second stage 
was a conditional logistic regression appropriate for the matched design, whereas in HPFS 
and NHS, the second stage was an unconditional logistic regression adjusted for matching 
factors. For HPFS and NHS, we restricted instrumental variable analyses to individuals of 
Caucasian ancestry in sensitivity analyses. The risk estimates resulting from the instrumental 
variable analysis display the association between 2-fold genetically determined higher 
adiponectin in relation to risk of colorectal cancer. Pooled associations were determined 
using random effects model and potential heterogeneity was assessed. We performed over-
identification tests to evaluate whether the Mendelian Randomization estimates are of 
similar magnitude across the multiple genetic instruments (i.e. individual SNPs included in 
the ADIPOQ allele score) (28). Finally, to increase statistical power, we performed a 
summary instrumental variable analysis using published data on genetic associations with 
adiponectin and colorectal cancer in a likelihood-based approach (13). Parameters for the 
association between the SNPs included in the ADIPOQ allele score and circulating 
adiponectin were taken from GWAS data (20) and parameters for the association between 
the SNPs and colorectal cancer were derived from the analysis in GECCO (11). Because 
summary instrumental variable analysis can be biased when correlated SNPs are included 
(13), we omitted rs266729 from this analysis, because it is in linkage disequilibrium with 
rs6810075 (r2 =0.5).
All statistical tests are two-sided with significance at the 5% level. Instrumental variable 
analyses were performed using the STATA SE 12 (StataCorp, College Station, Texas, USA). 
Summary instrumental variable analyses were performed with a publicly available R-Studio 
application (Foundation for Statistical Computing, Vienna, Austria). All other analyses were 
performed using SAS (for EPIC data: SAS Enterprise Guide 4.3; for HPFS and NHS data: 
SAS 9.3; SAS Institute Inc., Cary, North Carolina, USA).
Results
Baseline characteristics of study participants in EPIC, HPFS and NHS are displayed in Table 
1. In EPIC and HPFS, incident colorectal cancer cases had statistically significantly higher 
body mass index (BMI) and waist circumference than controls at baseline, whereas in NHS, 
these anthropometric measures did not differ between case and control participants. In EPIC, 
colorectal cancer cases consumed more alcohol and red and processed meat than control 
participants, whereas in the US cohorts, no such differences were observed. Other 
potentially confounding factors including physical activity and fiber intake did not differ 
remarkably between cases and controls in any study. In EPIC and HPFS, but not in NHS, 
adiponectin concentrations were lower in cases than in control participants in univariate 
comparisons.
Of the 14 ADIPOQ SNPs available for analysis in EPIC, five SNPs were statistically 
significantly associated with circulating adiponectin (Table 2). Each unit of the GWAS-
based ADIPOQ allele score was associated with 6.5 % (95% CI 3.6, 9.4) higher adiponectin. 
The ADIPOQ allele score explained 3.2% of the interindividual variation in adiponectin 
concentrations (F-value 20.2). In HPFS, three of the 19 genotyped SNPs were statistically 
significantly associated with adiponectin concentrations (Table 3). Each unit of the ADIPOQ 
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allele score was associated with 7.7 % (95% CI 0.9, 14.9) higher adiponectin (F-value 5.0). 
In NHS, six of the 19 available SNPs were statistically significantly associated with 
circulating adiponectin. The ADIPOQ allele score was associated with 7.7 % (95% CI 4.1, 
11.3) higher adiponectin concentrations and explained 3.6% of the interindividual variation 
in circulating adiponectin (F-value 18.8).
Potentially confounding factors assessed in the three cohorts did not differ remarkably 
across categories (approximate tertiles) of the ADIPOQ allele score (all P-values >0.05, 
supplemental table 1).
The ADIPOQ allele score was not statistically significantly associated with risk of colorectal 
cancer (pooled OR per score-unit 0.97, 95% CI 0.91, 1.04) in logistic regression analysis 
(table 4). This result was not altered when logistic regression analyses were restricted to 
Caucasian individuals in HPFS and NHS (pooled OR 0.97, 95% CI 0.91, 1.04). In the 
instrumental variable analysis taking measured adiponectin and ADIPOQ genetic variation 
in our study population simultaneously into account (table 5), using the ADIPOQ allele 
score as instrumental variable, genetically determined two-fold higher adiponectin was not 
statistically significantly associated with lower risk of colorectal cancer (pooled OR 0.73, 
95% CI 0.40, 1.34). These associations were not altered by restriction to Caucasians in 
HPFS and NHS (pooled OR 0.73, 95% CI 0.41, 1.33). Over-identification tests suggested 
that the Mendelian Randomization estimates for colorectal cancer risk were similar across 
the individual SNPs included in the ADIPOQ allele score (P-values testing the null-
hypothesis of identical effects across instruments were 0.64 in EPIC, 0.81 in HPFS and 0.52 
in NHS).
In the summary instrumental variable analysis using published data, no association between 
genetically determined higher adiponectin and risk of colorectal cancer was observed (OR 
per 2-fold higher adiponectin 0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 
1.01 in men) using the four SNPs rs1730539, rs17366568, rs1501299 and rs6810075 as 
instrumental variables.
Discussion
In this Mendelian Randomization analysis using data from three nested case-control studies 
of large prospective cohorts, we did not find evidence for a causal contribution of high 
adiponectin levels to lower risk of colorectal cancer. However, adiponectin concentrations 
were genetically determined only to a limited extent, which limited statistical power for our 
Mendelian Randomization analysis.
In a genetic association meta-analysis, the minor alleles of three ADIPOQ SNPs (rs1501299, 
rs2241766, rs266729) were associated with colorectal cancer risk (32), but associations were 
only seen in Asians and not in Caucasians. Individual SNPs at the ADIPOQ loci 
(rs17300539, rs17366568, rs17366743, rs1501299, rs3774261 (the proxy SNPs rs2241766 
was used in GECCO), rs6810075, rs266729, rs6773957, rs6444175, rs1063538), including 
those incorporated in the ADIPOQ allele score in the present study, were unrelated to risk of 
colorectal cancer in GECCO (11). In the same study, the allele-sum of 16 SNPs that have 
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been related to higher adiponectin concentrations in previous GWAS were combined in a 
genetic score, which was not related to colorectal cancer risk in women (OR per ten-allele 
increment 1.08, 95% CI 0.95, 1.22) or men (OR 1.01, 95% CI 0.90, 1.13). In contrast, in a 
two-sample Mendelian Randomization meta-analysis (33) using the ADIPOQ SNP 
rs2241766 as instrumental variable, 1 mg/L genetically determined higher adiponectin was 
associated with a 20–40% higher risk of colorectal cancer.
The strength of our study is the ability to jointly investigate adiponectin, genetic variation in 
the ADIPOQ gene and risk of colorectal cancer. In contrast to a two-sample Mendelian 
Randomization design, a full sample design, where genetic information and intermediate 
phenotype data (i.e. measured adiponectin concentration) are available in the same study 
participants, generally requires less assumptions and allows for systematic evaluation of 
instrumental variable assumptions (34). Thus, we were able to estimate the strength of the 
association between the ADIPOQ SNPs as well as the ADIPOQ allele score and adiponectin 
concentrations in our sample, thereby showing that the first Mendelian Randomization 
assumption was fulfilled. Furthermore, we showed that potentially confounding lifestyle 
factors did not vary substantially across categories of the instrumental variable, i.e. the 
second Mendelian Randomization assumption was also satisfied (35). It should be noted that 
only potentially confounding factors measured in the three studies could be investigated, 
thus, it cannot be entirely excluded that unmeasured confounders varied by categories of the 
ADIPOQ allele score. Assessment of the third Mendelian Randomization assumption 
(instrumental variable is associated with the outcome only through the intermediate 
exposure of interest, i.e. no pleiotropy) is not as straightforward, but the use of multiple 
SNPs as instrumental variables argues against unknown pleiotropy if the Mendelian 
Randomization estimates are similar across the multiple independent instruments, which was 
confirmed in our samples by the non-significant over-identification test results. Furthermore, 
the genetic variants used as instrumental variables were restricted to the ADIPOQ gene and 
therefore likely act directly on the adiponectin trait, which argues also against pleiotropic 
effects (27).
However, our study has also several limitations: Given the limited genetic determination of 
adiponectin concentrations, our sample sizes from three nested case-control studies of 
prospective cohorts was limited to derive robust causal estimates. The ADIPOQ allele score 
applied here explained only a low proportion (2.9%–3.6%) of the interindividual variation in 
adiponectin concentrations. With this genetic instrument and our sample size, the minimal 
OR that could have been detected with 80% statistical power was 0.61 per standard 
deviation in adiponectin, which is a stronger association than has been observed in most 
observational studies (8). Even with the relatively large sample size in GECCO (7,020 cases, 
7,631 controls) no association between a genetic score of variants associated with 
adiponectin and colorectal cancer was detected (11). Furthermore, in our summary data 
instrumental variable analysis, genetically determined higher adiponectin was not associated 
with colorectal cancer risk (minimal detectable OR with 80% power: 0.76 per standard 
deviation in adiponectin). A much larger sample size (n=33,960 cases, 33,960 controls) 
would be necessary to detect a moderate effect (e.g. OR 0.89 per 1 SD as observed in EPIC 
(6)) of adiponectin and colorectal cancer. Therefore, with our study and the summary 
instrumental variable analysis based on GECCO, we cannot rule out causality in the 
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association between circulating adiponectin and risk of colorectal cancer. Although it has 
been suggested that the 2-stage instrumental variable estimator may result in biased 
estimates under case-control sampling, it has been shown to be unbiased under the null 
hypothesis of no causal effect as in the present study (36).
In conclusion, this Mendelian Randomization meta-analysis using individual data from three 
nested case-control studies of prospective cohorts does not support a causal effect of 
circulating adiponectin on colorectal cancer risk. This lack of association may be related to 
the limited genetic determination of adiponectin and the limited sample size. Therefore, 
larger Mendelian Randomization studies are necessary to clarify whether adiponectin is 
causally related to lower risk of colorectal cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Directed acyclic graph (DAG) for Mendelian Randomization Study on adiponectin and 
colorectal cancer risk. X: modifiable exposure of interest; Y: outcome; C: confounder(s); Z: 
instrumental variable. NOTE: The effect of Z on Y should be mediated only through X (no 
pleiotropy), therefore this line is dashed. Associations [ZX] and [ZY] are used to estimate 
the causal effect of a biomarker on an outcome circumventing residual confounding and 
reverse causation.
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